Skip to main content

A nomogram based on CT texture features to predict the response of patients with advanced pancreatic cancer treated with chemotherapy



This study aimed to evaluate the predictive value of computed tomography (CT) texture features in the treatment response of patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy.


This study enrolled 84 patients with APC treated with first-line chemotherapy and conducted texture analysis on primary pancreatic tumors. 59 patients and 25 were randomly assigned to the training and validation cohorts at a ratio of 7:3. The treatment response to chemotherapy was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST1.1). The patients were divided into progressive and non-progressive groups. The least absolute shrinkage selection operator (LASSO) was applied for feature selection in the training cohort and a radiomics signature (RS) was calculated. A nomogram was developed based on a multivariate logistic regression model incorporating the RS and carbohydrate antigen 19-9 (CA19-9), and was internally validated using the C-index and calibration plot. We performed the decision curve analysis (DCA) and clinical impact curve analysis to reflect the clinical utility of the nomogram. The nomogram was further externally confirmed in the validation cohort.


The multivariate logistic regression analysis indicated that the RS and CA19-9 were independent predictors (P < 0.05), and a trend was found for chemotherapy between progressive and non-progressive groups. The nomogram incorporating RS, CA19-9 and chemotherapy showed favorable discriminative ability in the training (C-index = 0.802) and validation (C-index = 0.920) cohorts. The nomogram demonstrated favorable clinical utility.


The RS of significant texture features was significantly associated with the early treatment effect of patients with APC treated with chemotherapy. Based on the RS, CA19-9 and chemotherapy, the nomogram provided a promising way to predict chemotherapeutic effects for APC patients.

Peer Review reports


Pancreatic cancer is the seventh leading cause of cancer death, and its incidence and mortality have been stable. It has been predicted that pancreatic cancer will exceed breast cancer as the third leading cause of cancer death by 2025 [1]. The 5-year survival rates of pancreatic cancers in Nordics countries is 6% [2]. Unfortunately, about 80–85%of patients with pancreatic cancer are found to be advanced or metastatic which precludes curative resection [3]. Presently, most patients with advanced pancreatic cancer are treated with chemotherapy. The first-line chemotherapy includes FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, leucovorin), gemcitabine alone or combined with albumin-bound nab-paclitaxel [4, 5]. Despite significant progress in chemotherapy regimen, patients with APC respond differently to it. Previous studies showed that patients present poor responses to gemcitabine, which can be caused by the low expression of human equilibrative nucleoside transporter 1 (hENT1). However, the expression of hENT1 is not a routine detection in clinical practice and a large propotion of patients with APC even not received gemcitabine as first-line chemotherapy [6]. Among these problems, how to accurately evaluate the efficacy of chemotherapy at an early stage is still a challenging problem for clinicians when making clinical treatment decisions. Thus, there is an urgent need to find potential biomarkers to identify patients who can benefit from chemotherapy.

CT, compared with other effective methods like endoscopic ultrasound, is a noninvasive method in the diagnosis and treatment effect evaluation of pancreatic cancer [7]. However, conventional CT cannot quantitatively analyze tumor heterogeneity or predict therapeutic effects [8]. Fortunately, with the development of artificial intelligence, radiomics has played an important role in extracting quantitative features in medical images, which can be investigated to predict the efficacy and prognosis in targeted therapies, immunotherapies and radiotherapy [9]. Texture analysis is composed of various mathematical techniques, which can describe the grey-level patterns of images and play an important role in evaluating the spatial organization of different tissues and organs [10].

Several studies have shown that texture analysis can be used to predict treatment response in pancreatic cancer. For example, Nasief et al. found delta radiomics can be used as a biomarker for early prediction of treatment response in neoadjuvant chemoradiation therapy [11]. Simpson et al. found radiomics features may contain predictive information about response to treatment for PDAC patients undergoing stereotactic body radiotherapy (SBRT) [12]. Yue et al. found the predictive value of combining clinical features with PET-CT texture features in patients undergoing radiotherapy [13]. Nasief et al. found that combining delta-radiomics features and CA 19-9 levels results in an earlier prediction of good and bad responders undergoing neoadjuvant chemoradiation therapy [14]. To date, whether there is a correlation between CT texture features and first-line chemotherapy efficacy in patients with APC remains to be elucidated. Thus, this study aimed to determine the predictive value of pre-treatment CT texture features in APC patients receiving first-line chemotherapy.

Materials and methods


We retrospectively analyzed CT images of APC patients treated at Changzhou Second People’s Hospital Affiliated to Nanjing Medical University, between September 2016 and June 2019. They were randomly divided into a training cohort with 59 patients and a validation cohort with 25 patients. The inclusion criteria were as follows: (1) newly diagnosed and pathologically confirmed pancreatic adenocarcinoma; (2) absence of concurrent cancers at other sites; (3) TNM stage III or IV according to the 8th edition of the TNM staging system; (4) no prior history of radiotherapy, chemotherapy, or other treatments; (5) complete CT imaging data before chemotherapy and after two cycles of chemotherapy; (6) complete baseline clinicopathological features, including the patients’ age, sex, chemotherapy regimen, treatment effect ,tumor location, ECOG PS, TNM stage, CA19-9. The exclusion criteria were as follows: (1) failure to complete the prescribed chemotherapy regimen as scheduled; (2) incomplete clinical data at baseline; (3) poor image quality. Demographic and clinicopathologic features were collected from the electronic medical records. Informed consent was obtained from each patient, and ethical approval was accepted by the Ethics committees of Changzhou Second People’s Hospital Affiliated to Nanjing Medical University.

Treatment response assessment

The short-term therapeutic response was evaluated based on the follow-up CT imaging before the third cycle of chemotherapy using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) [15]. In our study, the patients were divided into two groups: with progressive disease (PD) and without progressive disease (SD or PR or CR).

CT image acquisition

Contrast-enhanced CT examinations were performed using a 128-row dual-source CT scanner (SOMATOM Definition Flash, Siemens, Germany) at 120 kV, tube current modulation, and 1 mm reconstructed section thickness. All patients were instructed to fast for at least 8 h before administering intravenous contrast (Iohexol, 1.5mL per kilogram of body weight, at a rate of 3 ml/s). After the injection of contrast agent, patients were subjected to double-helical scanning during the arterial and portal venous phases. The region of interest (ROI) was selected in primary pancreatic tumors during the arterial phase.

Image processing

ROIs were drawn on each slice of the primary pancreatic cancer using the software Labelme (version 3.11.2, Then, ROIs were extracted for texture analysis using Local Image Features Extraction (LIFEx, version 5.10, In the segmented tumors, the volume of interest (VOI) and histogram were calculated as first-order features. For calculations of second and high-order texture features, the number of grey levels used to resample the ROI content was set to 64.0. The Cartesian coordinates for spatial resampling were 2.0 mm (X-direction), 2.0 mm (Y-direction), and 1.0 mm (Z-direction). Texture features were evaluated using four texture matrices, including the grey-level co-occurrence matrix (GLCM), the grey-level run length matrix (GLRLM), the neighborhood grey-level different matrix (NGLDM), and the grey-level zone length matrix (GLZLM). We used the texture features of the largest cross-section of each tumor to predict therapy response.

Statistical analysis

Statistical analysis was conducted using R software (version 3.6.1, Institute for Statistics and Mathematics, Vienna, Austria) and SPSS statistical software (version 21.0, SPSS Inc, IBM, Armonk, NY, U.S.A.). The Chi-square test and independent samples t-test were used to investigate the differences between categorical variables and continuous variables. The correlations between texture variables were assessed using Pearson’s correlation coefficient with the R package “psych”. The LASSO was applied for feature selection, and RS was calculated by summing the selected features weighted by their β-coefficients, where RS = 3.37022285 * GLZLM_LZLGE + -0.04245328 * GLZLM_LGZE + 1.25470569 * Energy. The cut-off value of RS was determined according to the Youden’s J statistics (J = sensitivity + specificity − 1). Univariate analysis and multivariate logistic regression analysis were applied to investigate independent predictive factors. A nomogram was developed using the R package “rms” to predict the treatment effect, and the discrimination power of the nomogram was evaluated by calculating the C-index. In addition, calibration plot was generated using bootstrapping with 1000 resamples. To evaluate the clinical utility of the nomogram, DCA was performed by quantifying the net benefits at different threshold probabilities, and the clinical impact curve was performed by quantifying the number of high risk at each threshold probability.


Patients’ characteristics

The baseline clinicopathological characteristics of patients with APC in the training and validation cohorts were shown in Table 1. All the variables, including age, gender, Eastern Cooperative Oncology Group performance status (ECOG PS), chemotherapy, effect, TNM stage, primary tumor location and CA19-9, were comparable between the training and validation cohorts.

Table 1 Baseline clinicopathological characteristics of patients with APC

Correlations between texture parameters and treatment effect

The mean values and standard deviations of all texture features in the training cohort are shown in Table 2, and the values of these features were normalized for further analysis. There were no significant differences in GLCM parameters between the two groups with independent samples t-tests (P > 0.1, Table 2). In the histogram analysis, the progressive group showed a higher level of energy than the non-progressive group (P = 0.059). In addition, in the GLRLM analysis, the progressive group showed lower levels of LGRE (P = 0.028), SRLGE (P = 0.029), and LRLGE (P = 0.025), but higher levels of GLNU (P = 0.070) compared with the non-progressive group. In the NGLDM analysis, only Coarseness (P = 0.076) differed between the progressive and non-progressive groups. Moreover, in the GLZLM analysis, the progressive group had lower values of SZE (P = 0.064), LGZE (P = 0.019), SZLGE (P = 0.022), LZLGE (P = 0.020) and had greater levels of LZHGE (P = 0.062), GLNU (P = 0.067) than the non-progressive group.

Table 2 Texture features after normalization in the training cohort

Pearson’s correlation was used to investigate the correlations between texture parameters in the training cohort (Fig. 1). The results indicated that some pairs of these parameters showed significant correlations.

Fig. 1
figure 1

The correlations between texture parameters. The blue circles represent a positive correlation, and red circles represent a negative correlation. The darker the color of the circle is, the higher the correlation between the two texture parameters is

Texture features selection and radiomic score

Based on the LASSO regression model, three texture features related to the treatment effect were selected (Fig. 2). The final composition of the RS is: RS = 3.37022285 * GLZLM_LZLGE + -0.04245328 * GLZLM_LGZE + 1.25470569 * Energy. In this formula, each variable was weighted using its β-coefficient derived from the LASSO model. As shown in Table 3, the RS was an independent predictor in the multivariate logistic regression analysis (P = 0.044).

Fig. 2
figure 2

Selection of textural features using the LASSO regression. Red dots show average deviance values for each model at the given λ, and the vertical bars through the red dots indicate the upper and lower values of the binomial deviance. The vertical black lines show the optimal values of λ, where the model provides its best fit to the data

Table 3 Comparison between clinicopathological characteristics of APC according to treatment effect in the training cohort

Correlations between clinicopathological characteristics and treatment effect

As shown in Table 3, in the univariate analysis, the non-progressive group was treated more by combination therapy than the progressive group (P = 0.033). The progressive group had a higher level of CA19-9 compared with the non-progressive group (P = 0.012). However, other factors including age, gender, ECOG PS, TNM stage, and primary tumor location, showed no significant differences between the two groups. Furthermore, multivariate logistic regression analysis showed RS and CA19-9 were independent predictive factors (P < 0.05), and a trend was found for chemotherapy (P = 0.072) between the two groups.

Development and validation of the radiomics nomogram

A nomogram of the RS, CA19-9 and chemotherapy was constructed (Fig. 3A). The probability of high- or low-risk of disease progression after two cycles of chemotherapy was determined based on the total points of the radiomics nomogram. Furthermore, the calibration curve showed that the performance of the nomogram was similar to the ideal model and had good prediction capability (Fig. 3B). The nomogram achieved good discriminative ability in the training (C-index = 0.802) and validation (C-index = 0.920) cohorts. Comparably, the nomogram comprised of CA19-9 and chemotherapy only achieved moderate discriminative ability in the training (C-index = 0.705) and validation (C-index = 0.805) cohorts.

Fig. 3
figure 3

Developed the radiomics nomogram to predict the risk of disease progression after treatment with chemotherapy in a given patient (A). The calibration curves for the nomogram. The diagonal dotted line represents the perfect prediction of an ideal model. The apparent line represents the uncorrected performance of the nomogram, and the bias-corrected line represents the bias-corrected performance using bootstrapping with 1000 resamples (B)

The decision curve analysis (DCA) and clinical impact curve of the nomogram are shown in Fig. 4. The decision curves show that with a threshold probability > 0.4, using the radiomics nomogram to predict the efficacy of first-line therapy treatment response added more benefit than the scheme for all patients with a risk of disease progression after treatment or no patients with risk of disease progression after treatment.

Fig. 4
figure 4

Decision curve analysis for the radiomics nomogram (A). The gray line shows the assumption that all patients had the risk of disease progression after treatment. The black line represents the assumption that no patients had the risk of disease progression after treatment. Clinical impact curve for the radiomics nomogram. The red curve represents the number of people classified by the nomogram as positive (high risk) at each threshold probability. The curve (Number high risk with event) is the number of true positives at each threshold probability (B)


In this study, RS was identified as a potential predictive biomarker for patients with APC treated with first-line chemotherapy. Furthermore, we integrated CA19-9, chemotherapy and RS to generate an innovative individualized radiomics model, in order to characterize PD responder and non-PD responder to first-line chemotherapy and determine the clinical application of the radiomics model in patients with APC.

Previous studies have assessed the predictive significance of radiomics features for the treatment response in various malignancies [16,17,18]. Several studies have reported that pre-treatment radiomics features are associated with therapeutic effects and survival after adjuvant chemotherapy or radiotherapy in patients with PDAC [19, 20]. For unresectable APC patients, Cheng et al. reported that the combination of pretreatment SD with tumor size achieved an early prediction of treatment with chemotherapy [21]. Salinas-Miranda et al. found that the CT texture feature of cluster tendency was a significant prognostic factor treated with chemotherapy [22]. However, most studies focused on patients’ survival after treatment, but not the response. In this study, we found that the final selected texture features, GLZLM_LZLGE, GLZLM_LGZE, and Energy could predict the early efficacy of first-line chemotherapy in patients with APC, and distinguish the PD responder from non-PD responders. The RS was an independent predictor of the early response to chemotherapy in the training cohort (p < 0.05).

In this study, the final selected texture features, GLZLM_LZLGE, GLZLM_LGZE, and Energy, used for the RS were significant predictors of chemotherapeutic effects. Except for energy, which belongs to the first-order feature, the other two were second-order texture features belonging to the GLZLM. The LZLGE and LGZE were based on GLZLM, representing the size of the homogeneous regions with the same gray level in three dimensions without a specific orientation. LZLGE shows the distribution of the long homogeneous zones with low gray levels [23]. LGZE represents the distribution of low gray-level zones [24]. Several studies found that tumor heterogeneity was correlated with a poor response to chemotherapy or chemoradiotherapy in patients with APC [11, 25]. The lower was GLZLM_LZLGE or GLZLM_LGZE, the more heterogeneous was the texture. It has been reported that pancreatic cancer cells induce fibrosis by increasing extracellular matrix synthesis, which may lead to chemoresistance [26]. Thus, our results could be interpreted that the higher value of GLZLM_LZLGE or GLZLM_LGZE, the more homogeneous the tumor was, indicating less related fibrosis and higher sensitivity to chemotherapy. Energy reflects the homogeneity of gray distribution and the roughness of texture. The more homogeneous the image, the higher the energy [27]. However, it has also been reported that homogenous texture may indicate higher cellular density, reducing the amount of drug delivered to the tumor, leading to chemotherapy resistance [28]. Thus, our results could be interpreted that the higher value of Energy, the higher cellular density the tumor had, indicating lower sensitivity to chemotherapy.

Several studies found that the preoperative elevated CA19-9 level was a significant independent factor for predicting poor prognosis in patients with PDAC [29,30,31,32]. And other studies also found the baseline CA19-9 level was an independent risk factor for prognosis in patients with PDAC receiving Gemcitabine together with nab-paclitaxel [33, 34]. Our result was consistent with previous findings. Our study found that the CA19-9 level was an independent predictive marker in early chemotherapeutic effects for APC patients. The multivariate logistic regression analysis showed that the chemotherapy did not demonstrate enough predictive ability (P = 0.072), which made it seem unnecessary for inclusion in the model. However, several studies found that chemotherapy was an independent prognostic factor in the outcome of advanced pancreatic cancer patients [35, 36]. Moreover, several studies found that nab-paclitaxel plus gemcitabine combination therapy significantly improved survival than gemcitabine monotherapy in patients with APC [37, 38]. The lack of statistical significance of chemotherapy in the validation cohort may be due to the relatively small sample size and confounding by other factors [39]. The nomogram incorporating RS, CA19-9 and chemotherapy showed better discriminative ability in the training (C-index = 0.802) and validation (C-index = 0.920) cohorts than the one incorporating only CA19-9 and chemotherapy.

Based on the total points of the nomogram, a high- or a low-risk probability of disease progression after two cycles of chemotherapy treatment was determined. The nomogram calibration curve showed good agreement between the predicted and observed outcomes. The individualized prediction of treatment effect using the nomogram based on CT texture features and routine noninvasive tests is necessary for clinicians to make more precise decisions, which aligns with the trend of personalized medicine. Specifically, if a patient is determined to have a high-risk probability of disease progression according to the nomogram, more aggressive treatment is prone to be given. Patients with APC will benefit from this novel approach by providing risk stratification and decision support. Moreover, DCA and clinical impact curve were used to ensure that the nomogram it had good clinical utility. These findings indicated that it was an effective way to predict the early treatment response for APC patients by using CT texture feature-based nomogram.

Our study also has some limitations. First, the sample size is relatively small. We will continue to expand the sample size and conduct a multi-center study to confirm our findings. Second, manual segmentation was adopted in this study, which could introduce subjective bias to a certain extent. Third, our study only analyzed the images of patients from the arterial phase; although the lesions are well shown in the arterial phase, we still need to explore the noncontract phase or portal vein phase to enrich the results we investigated. Furthermore, our study is based on 2D images, and the lesion may not be fully reflected in the largest cross-section of the tumor, so we will use 3D images to extract the entire tumor in the future.

In conclusion, we developed a pre-treatment CT-based radiomics nomogram to predict the early efficacy of first-line chemotherapy in patients with APC, distinguish the PD responder from non-PD responder to first-line chemotherapy treatment. Our initial results showed that the nomogram, including RS, CA19-9 and chemotherapy provide a promising way to predict early chemotherapeutic effects for APC patients.

Data Availability

The datasets generated and analyzed during the current study are not publicly available due to the fact that they constitute an excerpt of research in progress but are available from the corresponding author on reasonable request.


  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.

    Article  Google Scholar 

  2. Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M, Andersson R. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol (London England). 2016;12(16):1929–46.

    Article  CAS  Google Scholar 

  3. De Dosso S, Siebenhüner AR, Winder T, Meisel A, Fritsch R, Astaras C, Szturz P, Borner M. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev. 2021;96:102180.

    Article  PubMed  Google Scholar 

  4. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2015;26(Suppl 5):v56–68.

    Article  Google Scholar 

  5. Tempero MA. NCCN Guidelines updates: pancreatic Cancer. J Natl Compr Cancer Network: JNCCN. 2019;17(55):603–5.

    CAS  Google Scholar 

  6. Perera S, Jang GH, Wang Y, Kelly D, Allen M, Zhang A, Denroche RE, Dodd A, Ramotar S, Hutchinson S, et al. hENT1 expression predicts response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Clin cancer research: official J Am Association Cancer Res. 2022;28(23):5115–20.

    Article  CAS  Google Scholar 

  7. Facciorusso A, Stasi E, Di Maso M, Serviddio G, Ali Hussein MS, Muscatiello N. Endoscopic ultrasound-guided fine needle aspiration of pancreatic lesions with 22 versus 25 gauge needles: a meta-analysis. United Eur Gastroenterol J. 2017;5(6):846–53.

    Article  Google Scholar 

  8. Liang Z, Huang A, Wang L, Bi J, Kuang B, Xiao Y, Yu D, Hong M, Zhang T. A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment. Aging. 2022;14(2):907–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. Cancer J Clin. 2019;69(2):127–57.

    Google Scholar 

  10. Scalco E, Rizzo G. Texture analysis of medical images for radiotherapy applications. Br J Radiol. 2017;90(1070):20160642.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nasief H, Zheng C, Schott D, Hall W, Tsai S, Erickson B, Allen Li X. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. NPJ precision oncology. 2019;3:25.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Simpson G, Spieler B, Dogan N, Portelance L, Mellon EA, Kwon D, Ford JC, Yang F. Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: a pilot study. Med Phys. 2020;47(8):3682–90.

    Article  PubMed  Google Scholar 

  13. Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. J Gastrointest Oncol. 2017;8(1):127–38.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Nasief H, Hall W, Zheng C, Tsai S, Wang L, Erickson B, Li XA. Improving treatment response prediction for Chemoradiation Therapy of Pancreatic Cancer using a combination of Delta-Radiomics and the clinical biomarker CA19-9. Frontiers in oncology 2019, 9:1464.

  15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J cancer (Oxford England: 1990). 2009;45(2):228–47.

    Article  CAS  Google Scholar 

  16. Yang F, Zhang J, Zhou L, Xia W, Zhang R, Wei H, Feng J, Zhao X, Jian J, Gao X, et al. CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy. Eur Radiol. 2022;32(3):1538–47.

    Article  CAS  PubMed  Google Scholar 

  17. Caruso D, Zerunian M, Ciolina M, de Santis D, Rengo M, Soomro MH, Giunta G, Conforto S, Schmid M, Neri E, et al. Haralick’s texture features for the prediction of response to therapy in colorectal cancer: a preliminary study. Radiol Med. 2018;123(3):161–7.

    Article  PubMed  Google Scholar 

  18. Park HJ, Kim JH, Choi SY, Lee ES, Park SJ, Byun JY, Choi BI. Prediction of therapeutic response of Hepatocellular Carcinoma to Transcatheter arterial chemoembolization based on Pretherapeutic dynamic CT and textural findings. AJR Am J Roentgenol. 2017;209(4):W211–20.

    Article  PubMed  Google Scholar 

  19. Liang L, Ding Y, Yu Y, Liu K, Rao S, Ge Y, Zeng M. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study. BMC Med Imaging. 2021;21(1):75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Tomaszewski MR, Latifi K, Boyer E, Palm RF, El Naqa I, Moros EG, Hoffe SE, Rosenberg SA, Frakes JM, Gillies RJ. Delta radiomics analysis of magnetic resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. Radiation Oncol (London England). 2021;16(1):237.

    Article  CAS  Google Scholar 

  21. Cheng SH, Cheng YJ, Jin ZY, Xue HD. Unresectable pancreatic ductal adenocarcinoma: role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Eur J Radiol. 2019;113:188–97.

    Article  PubMed  Google Scholar 

  22. Salinas-Miranda E, Khalvati F, Namdar K, Deniffel D, Dong X, Abbas E, Wilson JM, O’Kane GM, Knox J, Gallinger S, et al. Validation of prognostic Radiomic features from resectable pancreatic ductal adenocarcinoma in patients with Advanced Disease undergoing chemotherapy. Volume 72. Canadian Association of Radiologists journal = Journal l’Association canadienne des radiologistes; 2021. pp. 605–13. 4.

  23. Sheen H, Kim JS, Lee JK, Choi SY, Baek SY, Kim JY. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion. Abdom Radiol (New York). 2021;46(6):2839–49.

    Article  Google Scholar 

  24. Bracci S, Dolciami M, Trobiani C, Izzo A, Pernazza A, D’Amati G, Manganaro L, Ricci P. Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients. Radiol Med. 2021;126(11):1425–33.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Borhani AA, Dewan R, Furlan A, Seiser N, Zureikat AH, Singhi AD, Boone B, Bahary N, Hogg ME, Lotze M, et al. Assessment of response to Neoadjuvant Therapy using CT texture analysis in patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol. 2020;214(2):362–9.

    Article  PubMed  Google Scholar 

  26. Neumann CCM, von Hörschelmann E, Reutzel-Selke A, Seidel E, Sauer IM, Pratschke J, Bahra M, Schmuck RB. Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer. Hepatobiliary & pancreatic diseases international: HBPD INT. 2018;17(5):461–72.

    Article  CAS  Google Scholar 

  27. Ye J, Ling J, Lv Y, Chen J, Cai J, Chen M. Pulmonary adenocarcinoma appearing as ground-glass opacity nodules identified using non-enhanced and contrast-enhanced CT texture analysis: a retrospective analysis. Experimental and therapeutic medicine. 2020;19(4):2483–90.

    PubMed  PubMed Central  Google Scholar 

  28. Li X, Ma Q, Xu Q, Duan W, Lei J, Wu E. Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Curr Pharm Design. 2012;18(17):2404–15.

    Article  CAS  Google Scholar 

  29. Dong Q, Yang XH, Zhang Y, Jing W, Zheng LQ, Liu YP, Qu XJ. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. World J Surg Oncol. 2014;12:171.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Hong S, Song KB, Hwang DW, Lee JH, Lee W, Jun E, Kwon J, Park Y, Park SY, Kim N, et al. Preoperative serum carbohydrate antigen 19 – 9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. World J Gastrointest Surg. 2021;13(11):1423–35.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Izumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Shiihara M, Yamamoto M. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma. Scand J Gastroenterol. 2019;54(6):780–6.

    Article  PubMed  Google Scholar 

  32. Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG, Harmsen WS, et al. Factors Predicting Response, Perioperative Outcomes, and Survival following total neoadjuvant therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann Surg. 2021;273(2):341–9.

    Article  PubMed  Google Scholar 

  33. Izumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Matsunaga Y, Shiihara M, Yamamoto M. Evaluation of early prognostic factors in patients with pancreatic ductal adenocarcinoma receiving Gemcitabine together with nab-paclitaxel. Cancer diagnosis & prognosis. 2021;1(5):399–409.

    Article  Google Scholar 

  34. Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015, 107(2).

  35. Hang J, Xu K, Yin R, Shao Y, Liu M, Shi H, Wang X, Wu L. Role of CT texture features for predicting outcome of pancreatic cancer patients with liver metastases. J Cancer. 2021;12(8):2351–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Shi H, Chen Z, Dong S, He R, Du Y, Qin Z, Zhou W. A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study. BMC Gastroenterol. 2022;22(1):279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  Google Scholar 

  38. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin oncology: official J Am Soc Clin Oncol. 2011;29(34):4548–54.

    Article  Google Scholar 

  39. Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26(30):5512–28.

    Article  PubMed  Google Scholar 

Download references


This research was funded by grants from the National Natural Science Foundation of China (81902955), Natural Science Foundation of Jiangsu Province (BK20190161), and Project of Jiangsu Shuang Chuang Doctor (QT201904), Jiangsu province’s 2020 high-level health talents “six one project” top-notch talent research project (LGY2020036), Changzhou municipal health commission major project (ZD201913).

Author information

Authors and Affiliations



Conceptualization, J.H., H.S., and J.D.; methodology, J.L., J.H., and J.D.; software, J.L., J.H., and J.D.; validation, Y.L., M.M and H.S.; formal analysis, J.H., and J.D.; resources, J.L. J.H., and H.S.; writing-original draft preparation, J.L.; writing-review and editing, J.H., H.S., and J.D.; supervision, H.S.; project administration, J.H. All authors contributed to the article and approved the submitted version.

Corresponding authors

Correspondence to Junjie Hang or Haifeng Shi.

Ethics declarations

Ethical approval

The study was approved by the Ethics Committee of Changzhou Second People’s Hospital. All methods were carried out in accordance with relevant guidelines and regulations.Informed consent was obtained from all individual participants included in the study.

Consent of publication

Not applicable.

Conflict of interest

The authors declared that they have no conflict of interest.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, J., Du, J., Li, Y. et al. A nomogram based on CT texture features to predict the response of patients with advanced pancreatic cancer treated with chemotherapy. BMC Gastroenterol 23, 274 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • CT texture features
  • Advanced pancreatic cancer
  • Treatment response
  • Nomogram
  • Radiomics signature